ADmit Therapeutics
Santiago Lozano is an experienced professional in the field of finance and innovation, currently serving as Fund Director for multiple funds including Clave Innohealth, UN I+D+i Tech Transfer, and Navarra Tech Transfer. Santiago also contributes as an Expert Evaluator for organizations such as the European Innovation Council and SMEs Executive Agency, Eureka Network, and the European Health Investor Network. An active member of the Board of Directors at ADmit Therapeutics, Santiago holds a Master's degree in Financial Management from ESIC Business & Marketing School and a Licenciado in Economics from the University of Navarra.
This person is not in the org chart
This person is not in any teams
ADmit Therapeutics
ADmit Therapeutics is a biotechnology company that specializes in the development of early Alzheimer's disease diagnosis tests. The company's test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA by next-generation sequencing, enabling medical practitioners with aneasy way to detect early-stage Alzheimer.